KR20200011951A - 난청 치료에 사용하기 위한 뉴로트로핀 - Google Patents

난청 치료에 사용하기 위한 뉴로트로핀 Download PDF

Info

Publication number
KR20200011951A
KR20200011951A KR1020197035948A KR20197035948A KR20200011951A KR 20200011951 A KR20200011951 A KR 20200011951A KR 1020197035948 A KR1020197035948 A KR 1020197035948A KR 20197035948 A KR20197035948 A KR 20197035948A KR 20200011951 A KR20200011951 A KR 20200011951A
Authority
KR
South Korea
Prior art keywords
neurotropin
ngf
composition
hearing loss
neurotrophin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197035948A
Other languages
English (en)
Korean (ko)
Inventor
피졸 마리아 데
안드레아 아라미니
안나 시리코
마라 지폴리
주세피나 아세라
시몬 루카 마티올리
Original Assignee
돔페 파르마써티씨 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 돔페 파르마써티씨 에스.피.에이. filed Critical 돔페 파르마써티씨 에스.피.에이.
Publication of KR20200011951A publication Critical patent/KR20200011951A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197035948A 2017-05-24 2018-05-22 난청 치료에 사용하기 위한 뉴로트로핀 Ceased KR20200011951A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172659.9A EP3406259A1 (en) 2017-05-24 2017-05-24 Neurotrophins for use in the treatment of hearing loss
EP17172659.9 2017-05-24
PCT/EP2018/063310 WO2018215414A1 (en) 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss

Publications (1)

Publication Number Publication Date
KR20200011951A true KR20200011951A (ko) 2020-02-04

Family

ID=58772736

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035948A Ceased KR20200011951A (ko) 2017-05-24 2018-05-22 난청 치료에 사용하기 위한 뉴로트로핀

Country Status (11)

Country Link
US (1) US20200155647A1 (https=)
EP (2) EP3406259A1 (https=)
JP (1) JP2020520956A (https=)
KR (1) KR20200011951A (https=)
CN (1) CN110691607A (https=)
AU (1) AU2018274589A1 (https=)
BR (1) BR112019024504A2 (https=)
CA (1) CA3062744A1 (https=)
IL (1) IL270701A (https=)
RU (1) RU2019137430A (https=)
WO (1) WO2018215414A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240069256A (ko) * 2022-11-11 2024-05-20 단국대학교 천안캠퍼스 산학협력단 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093387A4 (en) * 2020-01-24 2024-04-24 Dompé farmaceutici S.p.A. GROWTH FACTOR FORMULATION FOR A CONDITION ASSOCIATED WITH AN OTIC EVENT
WO2022221351A1 (en) * 2021-04-13 2022-10-20 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu
EP4316505A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4501346A1 (en) * 2023-08-04 2025-02-05 Dompe' Farmaceutici S.P.A. Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
EP3328440A4 (en) * 2015-07-28 2019-01-16 Otonomy, Inc. TREATMENT WITH REDUCED TRK-B AND TRK-C ANTAGONISTS
CA2993645A1 (en) * 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240069256A (ko) * 2022-11-11 2024-05-20 단국대학교 천안캠퍼스 산학협력단 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐

Also Published As

Publication number Publication date
WO2018215414A1 (en) 2018-11-29
AU2018274589A1 (en) 2019-11-28
RU2019137430A (ru) 2021-06-24
EP3630159A1 (en) 2020-04-08
IL270701A (en) 2020-01-30
CN110691607A (zh) 2020-01-14
CA3062744A1 (en) 2018-11-29
EP3406259A1 (en) 2018-11-28
JP2020520956A (ja) 2020-07-16
RU2019137430A3 (https=) 2021-08-30
BR112019024504A2 (pt) 2020-06-23
US20200155647A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
KR20200011951A (ko) 난청 치료에 사용하기 위한 뉴로트로핀
Noushi et al. Delivery of neurotrophin-3 to the cochlea using alginate beads
Herran et al. In vivo administration of VEGF-and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease
Yuan et al. Curcumin improves neural function after spinal cord injury by the joint inhibition of the intracellular and extracellular components of glial scar
CN109689027A (zh) 甘油三酯耳用制剂及其用途
JP2018500394A (ja) スニチニブ製剤、及び緑内障の治療におけるその使用方法
Lebrun-Julien et al. Molecular and cell-based approaches for neuroprotection in glaucoma
García-Caballero et al. Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice
JP2008133285A (ja) 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
Yu et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel
US20160166701A1 (en) Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition
CA3087574A1 (en) Growth factor otic formulations
JP2020520956A5 (https=)
KR20170030093A (ko) 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
WO2022068241A1 (zh) 一种雷帕霉素制剂及其制备方法
EP3573636A2 (en) Neurotrophin mutants for treating hearing loss and other otic disorders
KR101354521B1 (ko) Ｐｅｇｔ／ｐｂｔ 블럭 공중합체를 기본으로 하는 인터페론의 방출 제어형 조성물
US9345749B2 (en) Method of treating intraoccular tissue pathologies with nerve growth factor
JP2025525989A (ja) 感音性難聴の治療のためのｎｇｆの鼻腔内投与
KR20120101390A (ko) Ｂｄｎｆ （뇌-유래 신경영양성 인자）에 기반한 안과용 조성물 및 그의 용도
US20180221451A1 (en) Long acting liraglutide compositions
Zhang et al. Repair of spinal cord injury using a time-specific four-dimensional multifunctional hydrogel with anti-inflammatory and neuronal differentiated microenvironments
EP3967706A1 (en) Aav mutant that efficiently infects supporting cells
WO2004075888A1 (ja) 角膜潰瘍治療剤
KR102653853B1 (ko) 약물　전달용 나노서스펜션 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210422

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231122

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231122

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I